Ruxolitinib for Therapy of Graft-versus-Host Disease

OBJECTIVE: Steroid-resistant graft-versus-host disease (GvHD) is a major challenge after allogeneic stem cell transplantation and associated with significant morbidity and mortality. There is no therapeutic standard defined beyond calcineurin inhibitors (CNI) and steroids. Furthermore, some patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Neumann, Thomas, Schneidewind, Laila, Weigel, Martin, Plis, Andrzej, Vaizian, Rem, Schmidt, Christian A., Krüger, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431395/
https://www.ncbi.nlm.nih.gov/pubmed/30956985
http://dx.doi.org/10.1155/2019/8163780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431395/
https://www.ncbi.nlm.nih.gov/pubmed/30956985
http://dx.doi.org/10.1155/2019/8163780

Ejemplares similares